Vasodilation

Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic

Retrieved on: 
Tuesday, November 28, 2023

“The start of our first-in-human study is a critical and exciting milestone.

Key Points: 
  • “The start of our first-in-human study is a critical and exciting milestone.
  • We look forward to seeing the potential of relaxin biology realized in patients,” said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic.
  • Because of these features, it offers a similarly broad range of potential therapeutic applications with significant benefits expected in cardio-pulmonary diseases.
  • We look forward to future clinical programs emerging from Tectonic’s platform.”

Vibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia (CLTI)

Retrieved on: 
Wednesday, November 1, 2023

Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.

Key Points: 
  • Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.
  • The study evaluated patients with infrapopliteal PAD and measured changes in foot perfusion and oxygenation as well as therapy tolerance, compliance and perception.
  • Patients in the trial had Rutherford class 3, 4 or 5 PAD, meaning severe claudication, ischemic rest pain or tissue loss including nonhealing ulcers.
  • “These early findings are promising for the future of non-invasive therapeutic options to treat chronic limb-threatening ischemia,” said Juliana Elstad, CEO at Vibrato.

Mangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business

Retrieved on: 
Friday, October 13, 2023

In the interview, Mr. Cohen begins by laying out the Company’s potent strategy for differentiating itself as a new breed of men’s health product provider.

Key Points: 
  • In the interview, Mr. Cohen begins by laying out the Company’s potent strategy for differentiating itself as a new breed of men’s health product provider.
  • According to Cohen, it starts with the idea of an “Erectile Function” pill instead of an “Erectile Dysfunction” pill.
  • Through that idea, Cohen believes the Company is positioning itself to tap into the relatively untapped younger demographic, which is mirrored by MangoRx’s dynamic marketing strategy.
  • Through its network of syndication, FMW programming reaches an estimated 540 million homes across US and international markets.

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, September 26, 2023

Deletion of APOE has been demonstrated to limit disease in multiple AD models.

Key Points: 
  • Deletion of APOE has been demonstrated to limit disease in multiple AD models.
  • In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies.
  • Key findings from the study include:
    NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice.
  • Additional studies to characterize NC181 as a potential therapeutic for AD and CAA are ongoing.

Hi-Tech Pharmaceuticals Launches KRANK3D® Pre-Workout Supplement

Retrieved on: 
Tuesday, August 1, 2023

This Hi-Tech exclusive technology leaves an abundance of L-arginine uncompromised in the muscle pool to create a wealth of NO, leading to maximum muscular vasodilation.

Key Points: 
  • This Hi-Tech exclusive technology leaves an abundance of L-arginine uncompromised in the muscle pool to create a wealth of NO, leading to maximum muscular vasodilation.
  • We believe that it will quickly become the go-to pre-workout supplement for aspiring athletes and gym goers looking to take their training to the next level."
  • "KRANK3D® is an innovative, intense, wicked pre-workout energy supplement that will be the Cadillas of our preworkout stable, which includes: Mesomorph®, Jack3D®, Ultimate Orang®, and Wicked®.
  • Not only does this new state-of-the-art formula hit harder, it also tantalizes your taste buds like never before.

Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Retrieved on: 
Monday, June 5, 2023

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced positive topline data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD). The exploratory study was designed to test the sensitivity of several patient reported outcome (PRO) efficacy endpoints and their ability to determine a treatment effect of Sildenafil Cream compared to placebo to inform the ongoing development of Sildenafil Cream. The study also served as a validation study of exploratory endpoints that could be candidate endpoints in a Phase 3 study of Sildenafil Cream. Although the exploratory study was underpowered to assess statistical significance, certain endpoints achieved statistical significance.

Key Points: 
  • The study also served as a validation study of exploratory endpoints that could be candidate endpoints in a Phase 3 study of Sildenafil Cream.
  • Sildenafil Cream is an investigational proprietary topical cream formulation of sildenafil specifically designed to increase blood flow to the genital tissue in women.
  • “We are very pleased with the topline data from the Phase 2b RESPOND study.
  • Daré plans to submit data from the Phase 2b RESPOND clinical study of Sildenafil Cream for publication in a peer-reviewed journal.

Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine

Retrieved on: 
Wednesday, May 31, 2023

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of the patient-centered study designed to elucidate the commonly reported symptoms, including severity of symptoms, associated with female sexual arousal disorder (FSAD). The publication, “Symptoms and associated impact in pre-and postmenopausal women with sexual arousal disorder: a concept elicitation study,” appears in The Journal of Sexual Medicine.

Key Points: 
  • The publication, “Symptoms and associated impact in pre-and postmenopausal women with sexual arousal disorder: a concept elicitation study,” appears in The Journal of Sexual Medicine.
  • The non-interventional study was conducted to identify and document the genital arousal symptoms that are the most problematic and most important symptoms to treat for women with FSAD.
  • The content validity study included in-depth, qualitative, semi-structured concept elicitation interviews with premenopausal (n=23) and postmenopausal (n=13) women who were clinically diagnosed with FSAD by a trained sexual medicine clinician.
  • FSAD is distinct from hypoactive sexual desire disorder (HSDD) in women, which is characterized primarily by a lack of sexual desire.

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

Retrieved on: 
Thursday, April 20, 2023

SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced initiation of screening and enrollment for a Phase 1 clinical study using thermography to assess the pharmacodynamic and pharmacokinetic characterization of Sildenafil Cream, 3.6% (Sildenafil Cream), a late-stage product candidate being developed as a potential new treatment for female sexual arousal disorder (FSAD). The quantitative pharmacokinetic and pharmacodynamic temperature data captured in a clinic setting in the study are expected to complement the patient reported outcome data collected in the ongoing Phase 2b RESPOND study, where the women use Sildenafil Cream in their home setting.

Key Points: 
  • Sildenafil is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra® for the treatment of ED in men.
  • Sildenafil Cream is an investigational proprietary topical cream formulation specifically designed to increase blood flow to the genital tissue in women.
  • “We are excited to announce that enrollment is underway in this important supplemental thermography study,” said Sabrina Martucci Johnson, President & CEO of Daré Bioscience.
  • These data are expected to complement forthcoming clinical findings from our Phase 2b RESPOND trial in preparation for a Phase 3 program.”
    The Phase 1 thermography study of Sildenafil Cream is expected to enroll approximately 15 women and be completed in 2023.

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

Retrieved on: 
Thursday, April 6, 2023

CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage biotech company focusing on inflammatory conditions, today announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No. 3132021, with claims focused on its proprietary strain of beneficial AOB, in the class of Nitrosomonas eutropha. The base patent term extends until April 15, 2035, excluding patent term extensions or coverage in additional related patent filings.

Key Points: 
  • -  AOBiome's clinical candidate B244 has demonstrated clinical efficacy on multiple therapeutic indications including: Mild-to-Moderate Atopic Dermatitis and associated Moderate-to-Severe Pruritus, and mild-to-moderate Acne Vulgaris
    CAMBRIDGE, Mass., April 6, 2023 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage biotech company focusing on inflammatory conditions, today announced that the European Patent Office (EPO) has issued a composition of matter patent, EP Patent No.
  • The base patent term extends until April 15, 2035, excluding patent term extensions or coverage in additional related patent filings.
  • This patent follows on other related issued composition of matter patents in Japan, Canada, India and Australia.
  • "Getting a composition of matter patent speaks to the unique aspects of this proprietary strain of AOB which has shown superior growth, stability and metabolic activity when compared to other strains.

Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023

Retrieved on: 
Thursday, February 9, 2023

Prolong Pharmaceuticals, a clinical stage biopharmaceutical company, today announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 (HEMERA-1) in acute ischemic stroke (AIS) patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai.

Key Points: 
  • Prolong Pharmaceuticals, a clinical stage biopharmaceutical company, today announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 (HEMERA-1) in acute ischemic stroke (AIS) patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai.
  • PP-007 (PEGylated carboxyhemoglobin, bovine) is a novel investigational biopharmaceutical product that improves microvascular perfusion while promoting transfer of oxygen to oxygen-deprived (hypoxic) cells and tissues.
  • HEMERA-1 is the first clinical trial of PP-007 in AIS.
  • PP-007’s multi-modal mechanism of action includes (1) increased blood flow and vasodilation of collateral circulation, (2) targeted delivery of oxygen in ischemic areas for 24 hours, and (3) plasma expansion.